Company / Total Debt
Xeris Biopharma Holdings, Inc. Total Debt History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$220.3M
FY2025
5-year range
$88.1M / $232.1M
FY2021-FY2025
Trend
-5.1%
vs FY2024
Sector context
#44 of 83
Health Care
What the data says
At $220M, Xeris Biopharma Holdings, Inc.'s total debt ranks #40 of 83 in the Health Care sector. Increased from $191M to $220M over the past 2 years.
Based on SEC 10-K filings.
$220M in FY2025 with a 5-year CAGR of +20.4%.
Increased from $191M to $220M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +5.6%
- 5-Year CAGR
- +20.4%
- 10-Year CAGR
- -
Sector benchmark
#40 of 83 in Health CareTop 47% of 83This company $220.3M Sector average $6.2B
▼
-96.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.4%, indicating consistent growth.
- In FY2025, total debt decreased 5.1% year-over-year.
- Ranks #44 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $220.3M | -5.1% |
| FY2024 | $232.1M | +21.6% |
| FY2023 | $190.9M | +2.1% |
| FY2022 | $187.1M | +112.4% |
| FY2021 | $88.1M | +1.2% |
| FY2020 | $87.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026